LENZ — LENZ Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815776 ·
Last close
$7.75
Market Cap
$243.00M
52W High
$14.97
52W Low
$6.61
ADV30
866,673
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,901,000 | 825,000 | -44,135,000 | -41,488,000 | 272,535,000 | 24,772,000 | 26,043,000 |
| Dec 2025 | 1,588,000 | — | -38,463,000 | -35,896,000 | 305,876,000 | 25,179,000 | 21,537,000 |
| Sep 2025 | 12,500,000 | — | -18,887,000 | -16,700,000 | 210,704,000 | 25,399,000 | 16,777,000 |
| Jun 2025 | 5,000,000 | — | -16,857,000 | -14,912,000 | 217,332,000 | 37,608,000 | 10,967,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,170,000
Investing CF
$-75,668,000
Financing CF
$149,745,000
CapEx
$-827,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,141,000
Inventory
$2,936,000
Receivables
$329,000
ST Investments
$267,168,000
EBIT TTM
$-91,138,000
Pretax Income TTM
$-81,625,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,989,000
EBITDA
$-117,980,000
Free Cash Flow
$-48,814,752
Enterprise Value
$-14,715,446
Total Cash
$258,384,992
Total Debt
$673,000
Shares Out
31,354,394
Trailing EPS
$-3.64
Book Value
$9.07
ROE
-49.7%
ROA
-31.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,088,000 | -91,138,000 | -82,127,000 | 305,876,000 | 21,537,000 | — | -69,170,000 |
| Dec 2024 | 0 | -58,610,000 | -49,769,000 | 215,304,000 | 11,220,000 | — | -59,391,000 |
| Dec 2023 | 0 | -72,429,000 | -69,968,000 | 70,376,000 | 163,088,000 | — | -60,380,000 |
| Dec 2022 | 15,000,000 | -10,483,000 | -10,811,000 | 46,951,000 | 71,120,000 | — | -4,091,000 |
TTM Snapshot
Revenues TTM
$1,086,000
NetIncome TTM
$-29,095,000
OpCashFlow TTM
$0
Assets (Latest)
$215,304,000
Forward EPS
$-3.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALEC | Alector, Inc. | $243.15M | $2.19 | — |
| HUMA | Humacyte, Inc. | $246.44M | $1.11 | — |
| FATE | FATE THERAPEUTICS INC | $250.60M | $2.15 | — |
| CGEN | COMPUGEN LTD | $250.65M | $2.65 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $251.14M | $2.71 | — |
News headlines (Yahoo Finance, 1h cache)
LENZ Therapeutics to Participate in Upcoming Investor Conferences
2026-05-26 12:00 · Yahoo
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade
2026-05-16 14:12 · Yahoo
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates
2026-05-14 13:16 · Yahoo
Top Midday Decliners
2026-05-12 17:59 · Yahoo
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls
2026-05-12 13:56 · Yahoo
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
2026-05-12 11:54 · Yahoo
LENZ Therapeutics Inc (LENZ) Q1 2026 Earnings Call Highlights: Strong Prescription Growth Amid ...
2026-05-12 07:07 · Yahoo
LENZ Therapeutics Q1 Earnings Call Highlights
2026-05-12 01:06 · Yahoo
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
2026-05-11 21:25 · Yahoo
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-11 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.